Evidence map›Paper›PMID 38432118›Full record

ArticleTuberculosis (Edinburgh, Scotland)2024

Computational drug repositioning identifies niclosamide and tribromsalan as inhibitors of Mycobacterium tuberculosis and Mycobacterium abscessus.

Jeremy J Yang, Aaron Goff, David J Wild, Ying Ding, Ayano Annis, Randy Kerber, Brian Foote, Anurag Passi, Joel L Duerksen, Shelley London and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tuberculosis (Edinburgh, Scotland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Integrative transcriptome-based drug repurposing in tuberculosis.bioRxiv : the preprint server for biology · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Jeremy J YangSchool of Informatics, Computing and Engineering, Indiana University, Bloomington, IN, USA; Data2Discovery, Inc., Bloomington, IN, USA; Department of Internal Medicine Translational Informatics Division, University of New Mexico, Albuquerque, NM, USA.
Aaron GoffDepartment of Global Health and Infection, Brighton & Sussex Medical School, University of Sussex, UK.
David J WildSchool of Informatics, Computing and Engineering, Indiana University, Bloomington, IN, USA; Data2Discovery, Inc., Bloomington, IN, USA.
Ying DingSchool of Informatics, Computing and Engineering, Indiana University, Bloomington, IN, USA; Data2Discovery, Inc., Bloomington, IN, USA; School of Information, Dell Medical School, University of Texas, Austin, TX, USA.
Ayano AnnisDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, NC, 27599, USA.
Randy KerberData2Discovery, Inc., Bloomington, IN, USA.
Brian FooteData2Discovery, Inc., Bloomington, IN, USA.
Anurag PassiDepartment of Pediatrics, UC San Diego, San Diego, CA, USA.
Joel L DuerksenData2Discovery, Inc., Bloomington, IN, USA.
Shelley LondonData2Discovery, Inc., Bloomington, IN, USA.
Ana C PuhlCollaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC, 27606, USA.
Thomas R LaneCollaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC, 27606, USA.
Miriam BraunsteinDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, NC, 27599, USA.
Simon J WaddellDepartment of Global Health and Infection, Brighton & Sussex Medical School, University of Sussex, UK.
Sean EkinsCollaborations Pharmaceuticals Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC, 27606, USA. Electronic address: sean@collaborationspharma.com.
Collaborations Pharmaceuticals (United States) · USBrighton and Sussex Medical School · GBIndiana University Bloomington · USUniversity of North Carolina at Chapel Hill · USUniversity of California San Diego · USUniversity of New Mexico · US

Funding

Centralized assay datasets for modelling support of small drug discovery organizationsR44GM122196 · NIGMS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN · 2018 to 2022
$3.3M
National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/R001669/1NIGMS NIH HHS R44 GM122196
6 · The paper itself

Abstract

Tuberculosis (TB) is still a major global health challenge, killing over 1.5 million people each year, and hence, there is a need to identify and develop novel treatments for Mycobacterium tuberculosis (M. tuberculosis). The prevalence of infections caused by nontuberculous mycobacteria (NTM) is also increasing and has overtaken TB cases in the United States and much of the developed world. Mycobacterium abscessus (M. abscessus) is one of the most frequently encountered NTM and is difficult to treat. We describe the use of drug-disease association using a semantic knowledge graph approach combined with machine learning models that has enabled the identification of several molecules for testing anti-mycobacterial activity. We established that niclosamide (M. tuberculosis IC

Indexed as

Mycobacterium abscessusMycobacterium Infections, NontuberculousMycobacterium tuberculosisSalicylanilidesTuberculosisDrug RepositioningHumansNiclosamideNontuberculous MycobacteriaNiclosamideSalicylanilidestribromsalanDrug discoveryMachine learningMycobacterium abscessusMycobacterium tuberculosisTranscriptome profiling

Identifiers

PMID38432118
PMCPMC10978224
OpenAlexW4392202181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.